HPMC Nasal Powder Particle Sizing for Longer Barrier Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nasal compositions, including those with hydroxypropyl methylcellulose (HPMC), lack specific guidance on mean particle size, leading to short-duration therapeutic effects and inadequate blocking of allergens and viruses, particularly for conditions like allergic rhinitis and respiratory diseases caused by coronaviruses.
Innovation Solution
Dry powder compositions with defined mean particle sizes ranging from 20 μm to 500 μm, preferably 60 μm to 150 μm, containing HPMC, a signaling agent, and optionally a biologically active agent, form a gel upon contact with nasal mucosa, creating a physical barrier to trap allergens and viruses while allowing drug diffusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional intranasal compositions (liquid compositions or powder compositions comprising little or no cellulose) are used, then administration is simple, but therapeutic effect duration is short (below 4 hours)
Solution Approach 1:
The patent uses composite materials by combining HPMC powder particles with therapeutic agents in a specific particle size range (20-500 μm). This composite structure allows the HPMC to form a gel matrix that retains moisture and therapeutic agents, extending the duration of action to over 6 hours while maintaining a relatively simple powder composition format for intranasal administration.
2Duration of action of moving object
If HPMC is used to form a protective gel in the nasal cavity, then therapeutic effect duration is extended (over 6 hours), but particle size control is lacking in prior art
Solution Approach 1:
The patent applies parameter changes by specifying a precise particle size range (20-500 μm, preferably 60-150 μm) for HPMC powder particles. This parameter control ensures optimal gel formation characteristics, moisture retention, and therapeutic agent release profile, thereby extending therapeutic effect duration while providing manufacturing precision that was previously lacking.
3Object-affected harmful factors
If HPMC powder is used to block allergen diffusion, then allergen uptake is reduced, but mean particle size effect on blocking efficiency is unknown
Solution Approach 1:
The patent optimizes allergen blocking efficiency by specifying HPMC powder particle sizes in the range of 20-500 μm (preferably 60-150 μm). This particle size range creates an optimal physical barrier structure in the nasal mucosa that effectively traps and blocks allergens while allowing sufficient gas exchange, thereby reducing allergen uptake without compromising nasal function.
4Reliability
If dry powder compositions with defined particle sizes are used, then gel formation and allergen blocking are improved, but composition formulation becomes more specific
Solution Approach 1:
The patent enhances gel formation consistency and reliability by specifying precise HPMC powder particle size parameters (20-500 μm, preferably 60-150 μm). This parameter specification ensures reproducible gel formation characteristics, moisture retention, and therapeutic agent release. While the formulation becomes more specific, it maintains practical simplicity by focusing on a single critical parameter (particle size) rather than complex multi-component systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide sustained protection against airborne allergens and viruses, including coronaviruses, by forming a gel that traps particles and allows drug delivery across the nasal mucosa, offering prolonged therapeutic effects.
Implementation Method 1
HPMC powders, and the gel that forms when they are administered to the nasal tract
Implementation Method 2
a protective gel is formed which slowly releases moisture and any therapeutic agent
Implementation Method 3
the diffusion of a house dust mite allergen through HPMC and agar gels
Data Source
AI summary
Compositions in homogenised powder form consisting of hydroxypropyl methylcellulose particles, and at least one chemical signalling agent in particle form, and optionally a biologically active agent, wherein the homogenised powder comprises particles having a mean particle diameter of ≥20 μm to ≤500 μmm uses and kits therefor.